New NS5B polymerase inhibitors for hepatitis C

Area of Science:

• Virology
• Hepatology
• Pharmacology

Background:

• Current chronic hepatitis C treatment with pegylated interferon and ribavirin has limited efficacy (50%).
• Targeted antiviral therapies offer a promising strategy for HCV eradication.
• Hepatitis C virus (HCV) polymerase is a key target for antiviral drug development.

Purpose of the Study:

• To review the progress in the development of HCV polymerase inhibitors.
• To discuss polymerase inhibitors that have entered clinical development.
• To highlight the potential of these inhibitors in treating chronic hepatitis C.

Main Methods:

• Review of recent clinical development of HCV polymerase inhibitors.
• Analysis of nucleoside/nucleotide analogues and non-nucleoside inhibitors.
• Evaluation of inhibitor activity, resistance profiles, and genotype specificity.

Main Results:

• Nucleos(t)ide analogues act as chain terminators at the HCV polymerase active site, showing pan-genotypic activity and a high barrier to resistance.
• Non-nucleoside inhibitors bind to allosteric sites, often exhibiting genotype-specific activity and potential for rapid resistance development.
• Both classes of inhibitors provide valuable options for managing HCV infection.

Conclusions:

• HCV NS5B polymerase inhibitors are crucial components of future effective anti-HCV therapies.
• These inhibitors will be used in combination regimens, including with interferon or other direct-acting antiviral agents.
• NS5B polymerase inhibitors represent a significant advancement in the fight against chronic hepatitis C.